← Back to Home

Getting Bacteria to Produce Medicine Inside Tumors: Engineered Bifidobacterium Suppresses Pancreatic Cancer in Mice

The low-oxygen environment of pancreatic tumors may offer a route for delivering immunotherapy. Researchers engineered gut bacteria to secrete immune signals inside tumors; experiments in mice showed that combining this approach with other treatments could further suppress tumors, but its safety and efficacy in humans remain to be verified.

By SURL BioNews

Pancreatic cancer is difficult to treat, partly because the environment surrounding tumors suppresses immune cells, making it difficult for them to mount an effective attack. A University of Chicago research team tried to tackle this barrier from within: engineering the gut bacterium Bifidobacterium longum into a therapeutic carrier that continuously produces immune-stimulating molecules after entering tumors. In mice, this strategy slowed pancreatic tumor growth.

The experimental therapy, called BifidoSumIL-2, combines bacterial delivery with protein engineering. In the study, published in Science Advances, the team engineered Bifidobacterium longum into a strain capable of secreting SumIL-2. This engineered form of interleukin-2 (IL-2) is designed to preferentially activate effector T cells involved in fighting cancer while reducing stimulation of regulatory T cells, which suppress immune responses.

The choice of bacteria as a carrier relates to oxygen conditions inside tumors. Bifidobacterium longum is suited to growth in oxygen-deprived environments, and many solid tumors contain low-oxygen regions. The researchers used this characteristic to encourage the strain to accumulate preferentially in tumors, concentrating production of immune-stimulating molecules where they need to act. Conventional IL-2 treatment can cause severe side effects and may also stimulate cells that suppress anticancer responses. The new design attempts to address both limitations, but whether it can reduce risks in humans has not been demonstrated.

According to the study abstract, the team administered the treatment systemically and observed suppression of tumor growth in both subcutaneous tumor models and orthotopic pancreatic ductal adenocarcinoma models, in which tumors grow in the pancreas. The University of Chicago’s account of the research also noted increased activity of CD8⁺ T cells involved in killing cancer cells within tumors after treatment. These results support the strain’s ability to alter the local immune environment, but mouse models still cannot fully capture the complexity of human pancreatic cancer.

Combination treatment was another key finding. In orthotopic tumor models, combining the bacterial therapy separately with chemotherapy, radiation therapy, or immunotherapy further limited tumor growth. The university’s account noted that this included anti-PD-L1 immunotherapy. This extends the research direction from using bacteria alone to exploring how local immune stimulation can work with other treatments. However, the additive effects observed in animal experiments cannot yet be taken to mean that a new therapy is available to patients.

BifidoSumIL-2 has not yet been tested in humans. The current experiments used administration by injection, and whether oral administration can achieve the same effect remains an open question. Researchers must also clarify the strain’s long-term safety, its effects outside tumors, and how long the immune response can be sustained. The significance of this work lies in proposing a route for bringing immune stimulation into pancreatic tumors; moving from local production of medicine inside mice to clinical use still requires further validation.

References

  1. ScienceDaily Top Health
  2. University of Chicago News
  3. PubMed / Science Advances